All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to our Co-Chair María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked for her top 3 breakthroughs in transplant for myeloma.
María-Victoria Mateos’s top 3 breakthroughs in transplant for myeloma
María-Victoria Mateos first talks about the emergence of measurable residual disease (MRD) as a possible surrogate marker for clinical outcome, or even for cure, in newly diagnosed multiple myeloma. She goes on to discuss the importance of autologous stem cell transplantation (auto-SCT) and its success in treating newly diagnosed patients. But despite this, in 2020, there have been preliminary findings suggesting that auto-SCT could be delayed or skipped in certain patients. María-Victoria Mateos concludes by mentioning bispecific antibodies and CAR T cells. In the future, these may be used in earlier stages of myeloma treatment and come to challenge the use of auto-SCT.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox